{"api":"OmniRx static API","version":"v1","status":"evaluation: contract may change before it is declared stable","edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z","envelope":"every JSON file with an answer uses {answer, receipts, as_of, edition, licence, unknown, disclaimer}","verify":"https://omnirx.org/editions.json","docs":"https://omnirx.org/api","routes":[{"path":"/api/v1/drugs/ozempic.json","summary":"Facts for ozempic: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/eliquis.json","summary":"Facts for eliquis: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/farxiga.json","summary":"Facts for farxiga: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/jardiance.json","summary":"Facts for jardiance: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/entresto.json","summary":"Facts for entresto: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/trulicity.json","summary":"Facts for trulicity: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/cosentyx.json","summary":"Facts for cosentyx: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/janumet.json","summary":"Facts for janumet: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/biktarvy.json","summary":"Facts for biktarvy: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/xarelto.json","summary":"Facts for xarelto: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/enbrel.json","summary":"Facts for enbrel: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/trelegy-ellipta.json","summary":"Facts for trelegy ellipta: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/anoro-ellipta.json","summary":"Facts for anoro ellipta: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/austedo.json","summary":"Facts for austedo: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/breo-ellipta.json","summary":"Facts for breo ellipta: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/calquence.json","summary":"Facts for calquence: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/cimzia.json","summary":"Facts for cimzia: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/entyvio.json","summary":"Facts for entyvio: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/erleada.json","summary":"Facts for erleada: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/ibrance.json","summary":"Facts for ibrance: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/imbruvica.json","summary":"Facts for imbruvica: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/januvia.json","summary":"Facts for januvia: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/kisqali.json","summary":"Facts for kisqali: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/lenvima.json","summary":"Facts for lenvima: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/linzess.json","summary":"Facts for linzess: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/novolog.json","summary":"Facts for novolog: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/ofev.json","summary":"Facts for ofev: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/orencia.json","summary":"Facts for orencia: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/otezla.json","summary":"Facts for otezla: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/pomalyst.json","summary":"Facts for pomalyst: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/rexulti.json","summary":"Facts for rexulti: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/stelara.json","summary":"Facts for stelara: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/tradjenta.json","summary":"Facts for tradjenta: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/verzenio.json","summary":"Facts for verzenio: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/vraylar.json","summary":"Facts for vraylar: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/xeljanz.json","summary":"Facts for xeljanz: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/xifaxan.json","summary":"Facts for xifaxan: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/xolair.json","summary":"Facts for xolair: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/drugs/xtandi.json","summary":"Facts for xtandi: identity, shortage state, prices, termination dates (lookup_drug and price_compare envelopes)"},{"path":"/api/v1/offers/ozempic.json","summary":"Manufacturer offers recorded for ozempic: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)"},{"path":"/api/v1/offers/eliquis.json","summary":"Manufacturer offers recorded for eliquis: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)"},{"path":"/api/v1/offers/cosentyx.json","summary":"Manufacturer offers recorded for cosentyx: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)"},{"path":"/api/v1/offers/biktarvy.json","summary":"Manufacturer offers recorded for biktarvy: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)"},{"path":"/api/v1/offers/xarelto.json","summary":"Manufacturer offers recorded for xarelto: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)"},{"path":"/api/v1/offers/linzess.json","summary":"Manufacturer offers recorded for linzess: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)"},{"path":"/api/v1/offers/stelara.json","summary":"Manufacturer offers recorded for stelara: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)"},{"path":"/api/v1/offers/wegovy.json","summary":"Manufacturer offers recorded for wegovy: savings card, self-pay price, free trial, with conditions and stated end dates (find_offers envelope)"},{"path":"/api/v1/dossier/ozempic.json","summary":"Everything recorded for ozempic in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/eliquis.json","summary":"Everything recorded for eliquis in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/farxiga.json","summary":"Everything recorded for farxiga in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/jardiance.json","summary":"Everything recorded for jardiance in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/entresto.json","summary":"Everything recorded for entresto in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/trulicity.json","summary":"Everything recorded for trulicity in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/cosentyx.json","summary":"Everything recorded for cosentyx in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/janumet.json","summary":"Everything recorded for janumet in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/biktarvy.json","summary":"Everything recorded for biktarvy in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/xarelto.json","summary":"Everything recorded for xarelto in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/enbrel.json","summary":"Everything recorded for enbrel in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/trelegy-ellipta.json","summary":"Everything recorded for trelegy ellipta in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/anoro-ellipta.json","summary":"Everything recorded for anoro ellipta in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/austedo.json","summary":"Everything recorded for austedo in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/breo-ellipta.json","summary":"Everything recorded for breo ellipta in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/calquence.json","summary":"Everything recorded for calquence in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/cimzia.json","summary":"Everything recorded for cimzia in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/entyvio.json","summary":"Everything recorded for entyvio in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/erleada.json","summary":"Everything recorded for erleada in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/ibrance.json","summary":"Everything recorded for ibrance in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/imbruvica.json","summary":"Everything recorded for imbruvica in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/januvia.json","summary":"Everything recorded for januvia in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/kisqali.json","summary":"Everything recorded for kisqali in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/lenvima.json","summary":"Everything recorded for lenvima in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/linzess.json","summary":"Everything recorded for linzess in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/novolog.json","summary":"Everything recorded for novolog in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/ofev.json","summary":"Everything recorded for ofev in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/orencia.json","summary":"Everything recorded for orencia in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/otezla.json","summary":"Everything recorded for otezla in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/pomalyst.json","summary":"Everything recorded for pomalyst in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/rexulti.json","summary":"Everything recorded for rexulti in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/stelara.json","summary":"Everything recorded for stelara in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/tradjenta.json","summary":"Everything recorded for tradjenta in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/verzenio.json","summary":"Everything recorded for verzenio in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/vraylar.json","summary":"Everything recorded for vraylar in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/xeljanz.json","summary":"Everything recorded for xeljanz in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/xifaxan.json","summary":"Everything recorded for xifaxan in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/xolair.json","summary":"Everything recorded for xolair in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/xtandi.json","summary":"Everything recorded for xtandi in one envelope: identity, price, generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist (drug_dossier envelope)"},{"path":"/api/v1/dossier/mounjaro.json","summary":"Everything recorded for Mounjaro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/humira.json","summary":"Everything recorded for Humira in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/revlimid.json","summary":"Everything recorded for Revlimid in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/vyndamax.json","summary":"Everything recorded for Vyndamax in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/dupixent.json","summary":"Everything recorded for Dupixent in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/skyrizi.json","summary":"Everything recorded for Skyrizi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/myrbetriq.json","summary":"Everything recorded for Myrbetriq in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/jakafi.json","summary":"Everything recorded for Jakafi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/ingrezza.json","summary":"Everything recorded for Ingrezza in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/repatha.json","summary":"Everything recorded for Repatha in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/invega-sustenna.json","summary":"Everything recorded for Invega Sustenna in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tresiba.json","summary":"Everything recorded for Tresiba in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/brukinsa.json","summary":"Everything recorded for Brukinsa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tagrisso.json","summary":"Everything recorded for Tagrisso in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/rinvoq.json","summary":"Everything recorded for Rinvoq in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/restasis.json","summary":"Everything recorded for Restasis in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/opsumit.json","summary":"Everything recorded for Opsumit in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/cabometyx.json","summary":"Everything recorded for Cabometyx in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/toujeo.json","summary":"Everything recorded for Toujeo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/nubeqa.json","summary":"Everything recorded for Nubeqa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/gemtesa.json","summary":"Everything recorded for Gemtesa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/venclexta.json","summary":"Everything recorded for Venclexta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/uptravi.json","summary":"Everything recorded for Uptravi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/spiriva-respimat.json","summary":"Everything recorded for Spiriva Respimat in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/lantus.json","summary":"Everything recorded for Lantus in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/prolia.json","summary":"Everything recorded for Prolia in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tyvaso-dpi.json","summary":"Everything recorded for Tyvaso Dpi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/vascepa.json","summary":"Everything recorded for Vascepa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/oxervate.json","summary":"Everything recorded for Oxervate in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/adempas.json","summary":"Everything recorded for Adempas in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/brilinta.json","summary":"Everything recorded for Brilinta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/promacta.json","summary":"Everything recorded for Promacta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/basaglar.json","summary":"Everything recorded for Basaglar in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/humalog.json","summary":"Everything recorded for Humalog in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/nuplazid.json","summary":"Everything recorded for Nuplazid in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/lumigan.json","summary":"Everything recorded for Lumigan in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/abilify-maintena.json","summary":"Everything recorded for Abilify Maintena in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tivicay.json","summary":"Everything recorded for Tivicay in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/nurtec-odt.json","summary":"Everything recorded for Nurtec ODT in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tremfya.json","summary":"Everything recorded for Tremfya in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/zenpep.json","summary":"Everything recorded for Zenpep in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/lynparza.json","summary":"Everything recorded for Lynparza in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/kesimpta.json","summary":"Everything recorded for Kesimpta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/triumeq.json","summary":"Everything recorded for Triumeq in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/taltz.json","summary":"Everything recorded for Taltz in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/albuterol-sulfate-hfa.json","summary":"Everything recorded for Albuterol Sulfate HFA in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/genvoya.json","summary":"Everything recorded for Genvoya in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/invega-trinza.json","summary":"Everything recorded for Invega Trinza in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/descovy.json","summary":"Everything recorded for Descovy in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/sprycel.json","summary":"Everything recorded for Sprycel in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/xiidra.json","summary":"Everything recorded for Xiidra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/spiriva-handihaler.json","summary":"Everything recorded for Spiriva Handihaler in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/orgovyx.json","summary":"Everything recorded for Orgovyx in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/stiolto-respimat.json","summary":"Everything recorded for Stiolto Respimat in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/inlyta.json","summary":"Everything recorded for Inlyta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/velphoro.json","summary":"Everything recorded for Velphoro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/ubrelvy.json","summary":"Everything recorded for Ubrelvy in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tasigna.json","summary":"Everything recorded for Tasigna in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/multaq.json","summary":"Everything recorded for Multaq in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/kerendia.json","summary":"Everything recorded for Kerendia in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/trintellix.json","summary":"Everything recorded for Trintellix in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/combivent-respimat.json","summary":"Everything recorded for Combivent Respimat in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/incruse-ellipta.json","summary":"Everything recorded for Incruse Ellipta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/radicava-ors.json","summary":"Everything recorded for Radicava Ors in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/odefsey.json","summary":"Everything recorded for Odefsey in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/actemra.json","summary":"Everything recorded for Actemra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/acthar.json","summary":"Everything recorded for Acthar in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/gattex.json","summary":"Everything recorded for Gattex in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/synthroid.json","summary":"Everything recorded for Synthroid in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/strensiq.json","summary":"Everything recorded for Strensiq in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/korlym.json","summary":"Everything recorded for Korlym in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/ojjaara.json","summary":"Everything recorded for Ojjaara in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/praluent.json","summary":"Everything recorded for Praluent in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/synjardy-xr.json","summary":"Everything recorded for Synjardy XR in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/advair-hfa.json","summary":"Everything recorded for Advair HFA in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/nucala.json","summary":"Everything recorded for Nucala in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/aimovig.json","summary":"Everything recorded for Aimovig in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/soliqua.json","summary":"Everything recorded for Soliqua in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/camzyos.json","summary":"Everything recorded for Camzyos in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/avonex.json","summary":"Everything recorded for Avonex in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/ninlaro.json","summary":"Everything recorded for Ninlaro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/invokana.json","summary":"Everything recorded for Invokana in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/aristada.json","summary":"Everything recorded for Aristada in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/caplyta.json","summary":"Everything recorded for Caplyta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/forteo.json","summary":"Everything recorded for Forteo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tibsovo.json","summary":"Everything recorded for Tibsovo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/qulipta.json","summary":"Everything recorded for Qulipta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/orserdu.json","summary":"Everything recorded for Orserdu in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/emgality.json","summary":"Everything recorded for Emgality in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tymlos.json","summary":"Everything recorded for Tymlos in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/copaxone.json","summary":"Everything recorded for Copaxone in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/premarin.json","summary":"Everything recorded for Premarin in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/rezurock.json","summary":"Everything recorded for Rezurock in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/vyvgart.json","summary":"Everything recorded for Vyvgart in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/humulin-r.json","summary":"Everything recorded for Humulin R in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/lokelma.json","summary":"Everything recorded for Lokelma in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/bosulif.json","summary":"Everything recorded for Bosulif in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/ultomiris.json","summary":"Everything recorded for Ultomiris in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/xtampza-er.json","summary":"Everything recorded for Xtampza ER in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/fasenra.json","summary":"Everything recorded for Fasenra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/zejula.json","summary":"Everything recorded for Zejula in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/takhzyro.json","summary":"Everything recorded for Takhzyro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/briviact.json","summary":"Everything recorded for Briviact in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/benlysta.json","summary":"Everything recorded for Benlysta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/teriparatide.json","summary":"Everything recorded for Teriparatide in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/krystexxa.json","summary":"Everything recorded for Krystexxa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/cabenuva.json","summary":"Everything recorded for Cabenuva in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/epidiolex.json","summary":"Everything recorded for Epidiolex in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/mekinist.json","summary":"Everything recorded for Mekinist in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/welireg.json","summary":"Everything recorded for Welireg in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/xigduo-xr.json","summary":"Everything recorded for Xigduo XR in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/victoza-3-pak.json","summary":"Everything recorded for Victoza 3-Pak in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/jaypirca.json","summary":"Everything recorded for Jaypirca in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/arnuity-ellipta.json","summary":"Everything recorded for Arnuity Ellipta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/scemblix.json","summary":"Everything recorded for Scemblix in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/wixela-inhub.json","summary":"Everything recorded for Wixela Inhub in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/soliris.json","summary":"Everything recorded for Soliris in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/ocrevus.json","summary":"Everything recorded for Ocrevus in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/vumerity.json","summary":"Everything recorded for Vumerity in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/metformin-hcl.json","summary":"Everything recorded for Metformin HCl in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/arikayce.json","summary":"Everything recorded for Arikayce in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/simponi.json","summary":"Everything recorded for Simponi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/truqap.json","summary":"Everything recorded for Truqap in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tezspire.json","summary":"Everything recorded for Tezspire in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/synjardy.json","summary":"Everything recorded for Synjardy in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/mavenclad.json","summary":"Everything recorded for Mavenclad in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/winrevair.json","summary":"Everything recorded for Winrevair in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tafinlar.json","summary":"Everything recorded for Tafinlar in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/kevzara.json","summary":"Everything recorded for Kevzara in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/rhopressa.json","summary":"Everything recorded for Rhopressa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/trazodone-hcl.json","summary":"Everything recorded for Trazodone HCl in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/xcopri.json","summary":"Everything recorded for Xcopri in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/lupron-depot.json","summary":"Everything recorded for Lupron Depot in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tecfidera.json","summary":"Everything recorded for Tecfidera in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/combigan.json","summary":"Everything recorded for Combigan in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/dulera.json","summary":"Everything recorded for Dulera in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/belbuca.json","summary":"Everything recorded for Belbuca in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/ayvakit.json","summary":"Everything recorded for Ayvakit in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/prednisolone-acetate.json","summary":"Everything recorded for Prednisolone Acetate in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/evrysdi.json","summary":"Everything recorded for Evrysdi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/insulin-lispro.json","summary":"Everything recorded for Insulin Lispro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/dificid.json","summary":"Everything recorded for Dificid in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/lumakras.json","summary":"Everything recorded for Lumakras in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/ventolin-hfa.json","summary":"Everything recorded for Ventolin HFA in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tepezza.json","summary":"Everything recorded for Tepezza in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/belsomra.json","summary":"Everything recorded for Belsomra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/aubagio.json","summary":"Everything recorded for Aubagio in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/sertraline-hcl.json","summary":"Everything recorded for Sertraline HCl in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/glyxambi.json","summary":"Everything recorded for Glyxambi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/amvuttra.json","summary":"Everything recorded for Amvuttra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/keytruda.json","summary":"Everything recorded for Keytruda in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tukysa.json","summary":"Everything recorded for Tukysa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/braftovi.json","summary":"Everything recorded for Braftovi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/fruzaqla.json","summary":"Everything recorded for Fruzaqla in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/relistor.json","summary":"Everything recorded for Relistor in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/varenicline-tartrate.json","summary":"Everything recorded for Varenicline Tartrate in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/wakix.json","summary":"Everything recorded for Wakix in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/auryxia.json","summary":"Everything recorded for Auryxia in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/vyzulta.json","summary":"Everything recorded for Vyzulta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/lybalvi.json","summary":"Everything recorded for Lybalvi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/simvastatin.json","summary":"Everything recorded for Simvastatin in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/vyvgart-hytrulo.json","summary":"Everything recorded for Vyvgart Hytrulo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/tabrecta.json","summary":"Everything recorded for Tabrecta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/trulance.json","summary":"Everything recorded for Trulance in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/pradaxa.json","summary":"Everything recorded for Pradaxa in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/cresemba.json","summary":"Everything recorded for Cresemba in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/omeprazole-sodium-bicarbonate.json","summary":"Everything recorded for Omeprazole-Sodium Bicarbonate in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/botox.json","summary":"Everything recorded for Botox in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/xphozah.json","summary":"Everything recorded for Xphozah in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/levemir.json","summary":"Everything recorded for Levemir in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/prevymis.json","summary":"Everything recorded for Prevymis in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/fotivda.json","summary":"Everything recorded for Fotivda in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/remicade.json","summary":"Everything recorded for Remicade in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/jublia.json","summary":"Everything recorded for Jublia in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/venlafaxine-hcl-er.json","summary":"Everything recorded for Venlafaxine HCl ER in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/erivedge.json","summary":"Everything recorded for Erivedge in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/lorbrena.json","summary":"Everything recorded for Lorbrena in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/miebo.json","summary":"Everything recorded for Miebo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/atrovent-hfa.json","summary":"Everything recorded for Atrovent HFA in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/risperdal-consta.json","summary":"Everything recorded for Risperdal Consta in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/isentress.json","summary":"Everything recorded for Isentress in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/diclofenac-epolamine.json","summary":"Everything recorded for Diclofenac Epolamine in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/buspirone-hcl.json","summary":"Everything recorded for Buspirone HCl in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/vonjo.json","summary":"Everything recorded for Vonjo in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/piqray.json","summary":"Everything recorded for Piqray in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/serostim.json","summary":"Everything recorded for Serostim in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/invega-hafyera.json","summary":"Everything recorded for Invega Hafyera in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/sucraid.json","summary":"Everything recorded for Sucraid in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/valacyclovir.json","summary":"Everything recorded for Valacyclovir in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/nuzyra.json","summary":"Everything recorded for Nuzyra in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/xospata.json","summary":"Everything recorded for Xospata in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/opzelura.json","summary":"Everything recorded for Opzelura in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/rebif.json","summary":"Everything recorded for Rebif in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/jynarque.json","summary":"Everything recorded for Jynarque in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/darzalex-faspro.json","summary":"Everything recorded for Darzalex Faspro in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/skyclarys.json","summary":"Everything recorded for Skyclarys in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/gocovri.json","summary":"Everything recorded for Gocovri in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/trijardy-xr.json","summary":"Everything recorded for Trijardy XR in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/nifedipine-er.json","summary":"Everything recorded for Nifedipine ER in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/xpovio.json","summary":"Everything recorded for Xpovio in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/stivarga.json","summary":"Everything recorded for Stivarga in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/mektovi.json","summary":"Everything recorded for Mektovi in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/evenity.json","summary":"Everything recorded for Evenity in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/fentanyl.json","summary":"Everything recorded for Fentanyl in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/dossier/betaseron.json","summary":"Everything recorded for Betaseron in one envelope: generic entry upper bound, label history, substitution, recalls, supply, trials, assistance and offers, policy, Part D spending (before rebates), biologic status and Part B payment limit where facts exist; this drug is not in the CMS negotiation file, so it carries no negotiated price (drug_dossier envelope)"},{"path":"/api/v1/findings/brand_vs_authorized_generic.json","summary":"Medicare negotiated price per unit against the pharmacy cost of an authorized generic of the same drug, with its recompute recipe"},{"path":"/api/v1/findings/ful_survey_share.json","summary":"Share of federal upper limits set by the pharmacy survey price, by period, with its recompute recipe"},{"path":"/api/v1/changes/last-30-days.json","summary":"Change events recorded since 2026-10-12 (shortage rows, program status, NADAC prices); regenerated with each build"},{"path":"/api/v1/termination/calendar.json","summary":"Every package with a termination date after today (newest CMS quarter)"},{"path":"/api/v1/states/insulin-caps.json","summary":"State insulin copay caps: one row per state we read, with the cap, its period, plan types, the quoted statute sentence, source URL, read date and fact id; a state not listed is unread, not lawless (state_facts envelope)"},{"path":"/api/v1/states/spap.json","summary":"State pharmaceutical assistance programs on the CMS best-price exclusion list: states, program names and counts; says nothing about eligibility or current operation (state_facts envelope)"},{"path":"/api/v1/states/index.json","summary":"Index of the state-level files and the states each one lists (state_facts envelope)"},{"path":"/api/v1/assistance/pack.json","summary":"Assistance programs, medicines, poverty table, and each program's dated status and ceiling proof (inputs of the matcher)"},{"path":"/api/v1/assistance/matcher.mjs","summary":"The finder's matching logic as an ES module (findPrograms, incomeCeilingFor, matchDrug, incomeStatus); run it locally on the pack"}],"templates":[{"path":"/conditions/index.json","summary":"Every condition hub with its fund counts, link and JSON twin","schema":"https://omnirx.org/api/v1/openapi.json#/components/schemas/ConditionIndex","parameters":[],"listing":null},{"path":"/conditions/ladders.json","summary":"Every route ladder (condition x drug) with its page and JSON twin: the way to enumerate /conditions/{condition}/{ingredient}.json","schema":"https://omnirx.org/api/v1/openapi.json#/components/schemas/LadderIndex","parameters":[],"listing":null},{"path":"/conditions/{condition}.json","summary":"One condition hub as data: the charitable funds we hold for it and the drugs whose FDA label names it","schema":"https://omnirx.org/api/v1/openapi.json#/components/schemas/ConditionHub","parameters":["condition"],"listing":"https://omnirx.org/conditions/index.json"},{"path":"/conditions/{condition}/{ingredient}.json","summary":"The six routes to paying for one drug for one condition, in a fixed order that is not a ranking, each with its source, read date and receipt","schema":"https://omnirx.org/api/v1/openapi.json#/components/schemas/RouteLadder","parameters":["condition","ingredient"],"listing":"https://omnirx.org/conditions/ladders.json"},{"path":"/fact/{id}.json","summary":"One recorded fact as stored: value, source, read date, licence label, verifying quote, edition root, and hashes of the exact stored text. Ids are the fact_id values in dossier receipts and ladder twins; not every fact in the edition has a page","schema":"https://omnirx.org/api/v1/openapi.json#/components/schemas/FactTwin","parameters":["id"],"listing":null},{"path":"/assistance/funds.json","summary":"Every charitable copay fund we hold with its status, the date the page gave and the date we read it","schema":"https://omnirx.org/api/v1/openapi.json#/components/schemas/FundBoard","parameters":[],"listing":null}],"stability":"evaluation: the shapes of these surfaces are checked against the schemas in /api/v1/openapi.json at every publish; fields may be added, and the contract may change before it is declared stable"}